Clinical trial • Phase III • Other
bosentan for Healthy volunteer
Phase III trial of bosentan for Healthy volunteer. 16 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteer
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 12-02-2026
- First CTIS Authorization Date
- 15-04-2026
Trial design
Phase III trial across 1 site in Germany.
- Target Sample Size
- 16
- Trial Duration For Participant
- 52
Recruitment
- Planned Sample Size
- 16
- Recruitment Window Months
- 1
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 16
Germany
- Earliest CTIS Part Ii Submission Date
- 10-04-2026
- Latest Decision Or Authorization Date
- 15-04-2026
- Processing Time Days
- 5
- Number Of Sites
- 1
- Number Of Participants
- 16
Sites
- Site Name
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Department Name
- Global Clinical Development & Operations
- Contact Person Name
- Thomas Gießmann
- Contact Person Email
- thomas.giessmann@boehringer-ingelheim.com
Sponsor
Primary sponsor
- Full Name
- Boehringer Ingelheim International GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- bosentan
- Active Substance
- bosentan
- Modality
- Small molecule
- Investigational Product Name
- zongertinib
- Active Substance
- zongertinib
- Modality
- Small molecule
Related trials
Other published trials that may interest you.